Use of basiliximab and daclizumab in kidney transplantation

Progress in Transplantation

Volumn 11, Issue 1, 2001, Pages 33-38

  Olyaei, A J ^a   Thi, K ^a   DeMattos, A M ^a   Bennett, W M ^a  

^a InnoVision Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; INTERLEUKIN 2 RECEPTOR ANTIBODY; MONOCLONAL ANTIBODY; STEROID;

ALLOGRAFT; ARTICLE; CLINICAL TRIAL; CYTOKINE PRODUCTION; DIALYSIS; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG MONITORING; DRUG SAFETY; DRUG USE; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LYMPHOCYTE PROLIFERATION; OPPORTUNISTIC INFECTION; PATIENT CARE; TREATMENT FAILURE;

EID: 0035088113     PISSN: 15269248     EISSN: None     Source Type: Journal    
DOI: 10.1177/152692480101100106     Document Type: Article

References (28)

1. The impact of an acute rejection episode on long-term renal allograft survival (t1/2)
2. The UNOS Scientific Renal Transplant Registry
3. The UNOS Scientific Renal Transplant Registry: Ten years of kidney transplants
4. The impact of acute rejection episodes on long-term graft function and outcome in 1347 primary renal transplants treated by 3 cyclosporine regimens
5. The clinical and experimental use of monoclonal antibodies to the IL-2 receptor
6. Human and humanized monoclonal antibodies: Preclinical studies and clinical experience
7. Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantation
8. New insights into therapy with monoclonal antibodies in allograft transplantation
9. Disposition of basiliximab, an interleukin-2 receptor monoclonal antibody, in recipients of mismatched cadaver renal allografts
10. Pharmacokinetics and immunodynamics of chimeric IL-2 receptor monoclonal antibody SDZ CHI 621 in renal allograft recipients
11. A phase I trial of humanized anti-interleukin 2 receptor antibody in renal transplantation
12. Prolonged immunosuppressive effect and minimal immunogenicity from chimeric (CD25) monoclonal antibody SDZ CHI 621 in renal transplantation
13. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients
14. Population pharmacokinetics and exposure-response relationships for basiliximab in kidney transplantation: The U.S. Simulect Renal Transplant Study Group
15. Constructing a prediction interval for time to reach a threshold concentration based on a population pharmacokinetic analysis: An application to basiliximab in renal transplantation
16. Basiliximab
17. Interleukin-2 receptor blockade with daclizumab to prevent acute rejection in renal transplantation
18. Reduction of acute renal allograft rejection by daclizumab: Daclizumab Double Therapy Study Group
19. Cytomegalovirus infections after treatment with daclizumab, an anti IL-2 receptor antibody, for prevention of renal allograft rejection: Roche Study Group
20. Sequential immunoprophylaxis in renal transplantation: Comparison of two doses of daclizumah to OKT-3 induction
21. One or two doses of daclizumab provide effective immunosuppression for renal transplant patients with high immunologic risk or with delayed graft function
22. Daclizumab induction for primary kidney transplantation recipients using tacrolimus, mycophenolate and steroids as maintenance immunosuppression
23. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody: United States Simulect Renal Study Group
24. Basiliximab significantly reduces the incidence of acute rejection in renal transplant patients receiving a triple therapy with azathioprine
25. A review of interleukin-2 receptor antagonists in solid organ transplantation
26. The use of antibodies against the IL-2 receptor in transplantation